Articles
| Open Access |
https://doi.org/10.55640/
ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN: AN ANALYSIS OF THE RESULTS OF THE MEGA STUDY ON THE USE OF MEXIDOL
Majidova Yo.N. , MD, PhD, Professor, Chief Neurologist of the Ministry of Health of the Republic of Uzbekistan, Head of the Department of Neurology, Pediatric Neurology, and Medical Genetics, Tashkent State Medical UniversityAbstract
The present paper provides a systematic review of the etiopathogenetic mechanisms underlying the development of attention deficit hyperactivity disorder (ADHD). Particular emphasis is placed on the role of neurometabolic imbalance, oxidative stress, and membranopathies in the pathogenesis of cognitive and behavioral dysfunction. The rationale for including neuroprotective agents in therapeutic protocols is substantiated. The results of the multicenter randomized double-blind placebo-controlled clinical study “MEGA” are presented, demonstrating the efficacy and safety profile of Mexidol (ethylmethylhydroxypyridine succinate) in the correction of the ADHD symptom complex in children aged six to twelve years.
Keywords
ADHD, neuroplasticity, oxidative stress, neurotransmitter metabolism, dopaminergic system, Mexidol, MEGA study, pharmacotherapy.
References
Polanczyk G., de Lima M.S., Horta B.L., et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis // American Journal of Psychiatry. - 2007. - Vol. 164, № 6. - P. 942-948.
Thomas R., Sanders S., Doust J., et al. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis // Pediatrics. - 2015. - Vol. 135, № 4. - P. 994-1001.
Faraone S.V., Banaschewski T., Coghill D., et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder // Neuroscience & Biobehavioral Reviews. - 2021. - Vol. 128. - P. 789-818.
Hatice Sezen, Hasan Kandemir, Emin Savik, Sultan Basmacı Kandemir,Fethiye Kilicaslan, Hasan Bilinc & Nurten Aksoy (2016) Increased oxidative stress inchildren with attention deficit hyperactivity disorder, Redox Report, 21:6, 248-253, DOI:10.1080/13510002.2015.1116729.
Verlaet AAJ, Breynaert A, Ceulemans B, et al. Oxidative stress and immune aberrancies in attention-deficit/hyperactivity disorder (ADHD): a case–control comparison // European Child & Adolescent Psychiatry. - 2019. - Vol. 28, № 5. - P. 719-729. https://doi.org/10.1007/s00787-018-1239-4.
Воронина Т.А. Мексидол: спектр фармакологических эффектов // Журнал неврологии и психиатрии им. С.С. Корсакова. - 2012. - № 12. - С. 86-90.
Хамитова Г.Р. Применение препарата Мексидол® в детской неврологической практике // Неврология. - 2012. - С. 100-101.
Cortese S., Adamo N., Del Giovane C., et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis // The Lancet Psychiatry. - 2018. - Vol. 5, № 9. - P. 727-738.
Swanson J.M., Kraemer H.C., Hinshaw S.P., et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment // Journal of the American Academy of Child & Adolescent Psychiatry. - 2001. - Vol. 40, № 2. - P. 168-179.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. - 2018.
Заваденко Н.Н., Суворинова Н.Ю., Батышева Т.Т., и др. Результаты многоцентрового двойного слепого рандомизированного плацебо-контролируемого клинического исследования по оценке эффективности и безопасности препарата Мексидол в лечении синдрома дефицита внимания с гиперактивностью у детей (МЕГА) // Журнал неврологии и психиатрии им. С.С. Корсакова. - 2022. - Т. 122, № 4. - С. 75-86. https://doi.org/10.17116/jnevro202212204175
Заваденко Н.Н., Суворинова Н.Ю., Заваденко А.Н. Возможности применения Мексидола в нейропедиатрии // Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. - 2023. - Т. 123, № 9-2. - С. 43-50. https://doi.org/10.17116/jnevro202312309243
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.